Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell support: Experience by the Italian Association of Pediatric Hematology and Oncology

Pediatric Blood and Cancer

Volumn 51, Issue 1, 2008, Pages 23-28

  Spreafico, Filippo ^a   Bisogno, Gianni ^b   Collini, Paola ^a   Jenkner, Alessandro ^c   Gandola, Lorenza ^a   D'Angelo, Paolo ^d   Casazza, Gabriella ^e   Piva, Luigi ^a   Luksch, Roberto ^a   Perotti, Daniela ^a   Pession, Andrea ^f   Fagioli, Franca ^g   Dallorso, Sandro ^h  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e UNIVERSITY OF PISA   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^h G GASLINI INSTITUTE   (Italy)

Author keywords

Autologous hematopoietic stem cell transplantation; High dose chemotherapy; Relapse; Wilms tumor

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE INTERVAL; FANCONI RENOTUBULAR SYNDROME; FEMALE; HIGH RISK PATIENT; HUMAN; KIDNEY DYSFUNCTION; MALE; NEPHRECTOMY; NEPHROBLASTOMA; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOCYTE COUNT; THROMBOPHILIA; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; ITALY; MALE; NEPHRECTOMY; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; WILMS TUMOR;

EID: 44149083336     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21524     Document Type: Article

References (24)

1. Grundy P, Breslow N, Green DM, et al. Prognostic factors for children with recurrent Wilms' tumor: Results from the Second and Third National Wilms' Tumor Study. J Clin Oncol 1989;7:638-647.
2. Miser JS, Tournade MF. The management of relapsed Wilms tumor. Hematol Oncol Clin North Am 1995;9:1287-1302.
3. Wilimas JA, Champion J, Douglass EC, et al. Relapsed Wilms tumor. Factors affecting survival and cure. Am J Clin Oncol 1985;8:324-328.
4. Pinkerton CR, Groot-Loonen JJ, Morris-Jones PH, et al. Response rates in relapsed Wilms' tumor. A need for new effective agents. Cancer 1991;67:567-571.
5. Dome JS, Liu T, Krasin M, et al. Improved survival for patients with recurrent Wilms tumor: The experience at St. Jude Children's Research Hospital. J Pediatr Hematol/Oncol 2002;24:192-198.
6. Pein F, Michon J, Valteau-Couanet D, et al. High-dose melphalan, etoposide and carboplatin followed by autologous stem cell rescue in pediatric high-risk recurrent Wilm's tumor: A French Society of Pediatric Oncology Study. J Clin Oncol 1998;16:3295-3301.
7. Kremens B, Gruhn B, Klingebiel T, et al. High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transplant 2002;30:893-898.
8. Campbell AD, Cohn SL, Reynolds M, et al. Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: The experience at Children's Memorial Hospital. J Clin Oncol 2004;22:2885-2890.
9. Abu-Ghosh AM, Krailo MD, Goldman SC, et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: A Children's Cancer group report. Ann Oncol 2002;13:460-469.
10. Tannous R, Giller R, Holmes E, et al. Intensive therapy for high risk (HR) relapsed Wilm's tumor (WT). A CCG-4921/POG-9445 study report. Proc ASCO 2000;19:588a (abstract n 2315).
11. Malogolowkin M, Cotton CA, Green DM, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 2008;50:236-241.
12. Pein F, Rey A, de Kraker J, et al. Multivariate analysis of adverse prognostic factors (APF) in children with recurrent (Rec) Wilms' tumor (WT) after initial treatment according to SIOP-6 or SIOP-9 strategies. Med Ped Oncol 1999;33:170 (abstract N. 111).
13. Green DM, Cotton CA, Malogolowkin M, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 2007;48:493-499.
14. Garaventa A, Hartmann O, Bernard JL, et al. Autologous bone marrow transplantation for pediatric Wilms' tumor: The experience of the European Bone Marrow Transplantation Solid Tumor Registry. Med Ped Oncol 1994;22:11-14.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
16. Peto R, Peto J. Asymptomatically efficient rank invariant test procedures. J R Stat Soc (A) 1972;135:185-198.
17. Spreafico F, Fossati Bellani F. Wilms tumor: Past, present and (possibly) future. Expert Rer Anticancer Ther 2006;6:249-258.
18. De Kraker J, Graf N, van Tinteren H, et al. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP trial): A randomised controlled trial. Lancet 2004;364:1229-1235.
19. Tournade MF, Lemerle J, Brunat-Mentigny M, et al. Ifosfamide is an active drug in Wilms' tumor: A phase II study conducted by the French Society of Pediatric Oncology. J Clin Oncol 1988;6:793-796.
20. Pein F, Pinkerton R, Tournade MF, et al. Etoposide in relapsed Wilms' tumor: A phase II study by the French Society of Pediatric Oncology. J Clin Oncol 1993;11:1478-1481.
21. De Camargo B, Melarango R, Saba e Silva N, et al. Phase II study of carboplatin as a single drug for relapsed Wilms' tumor: Experience of the Brazilian Wilms' Tumor Study Group. Med Pediatr Oncol 1994;22:258-260.
22. Pein F, Tournade MF, Zucker JM, et al. Etoposide and carboplatin: A highly effective combination in relapsed or refractory Wilms' tumor - A phase II study by the French Society of Pediatric Oncology. J Clin Oncol 1994;12:931-936.
23. Saylors RL, Stewart CF, Zamboni WC, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: A Pediatric Oncology Group Study. J Clin Oncol 1998;16:945-952.
24. Metzger ML, Stewart CF, Freeman BB, III., et al. Topotecan is active against Wilms' tumor: Results of a multi-institutional phase II study. J Clin Oncol 2007;25:3130-3136.